Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

• Status: Terminated
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to learn whether PPM-204 has an effect on lowering blood glucose (blood sugar) levels and is safe in treating people with type 2 diabetes.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Men and women of non-childbearing potential, 18 to 70 years old

• Subjects currently treated with diet and exercise alone and subjects receiving a single oral antidiabetic medication

• BMI > 23 and < 43

• For subjects currently treated with 1 antidiabetic medication: HbA1c is greater than or equal to 6.8% and less than or equal to 8.5%.

• For subjects not currently treated with antidiabetic medications: HbA1c is greater than or equal to 7.2% and less than or equal to 9.0%

Exclusion Criteria:

• Subjects requiring insulin therapy

• Subjects currently receiving 2 or more oral antidiabetic medications

• Subjects requiring systemic corticosteroids, unless treatment was discontinued at least 4 weeks before the screening visit

• Subjects receiving warfarin

• Subjects currently receiving thiazolidinediones, unless treatment was discontinued 8 weeks before the screening visit

• Significant diabetic complications (retinopathy, nephropathy, symptomatic neuropathy)